Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Day One Biopharmaceuticals, Inc.
DAWN
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.2B
$21.53
▲ 0.00%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$5.64 - $21.53
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 241.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Brain-penetrant drug design enabling CNS cancer treatment
- Focus on genetically defined cancers with precision targeting
- Experienced management team from leading oncology companies
- Oral formulation improving patient compliance versus IV therapies
Bear Case
1 risk
- Low volatility (beta -1.7).
Growth
Strong growth ahead
DAY101 Phase II clinical trial progression and potential FDA approval
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+79.1% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying DAWN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 5, 2026
Earnings recap unavailable for this period.
EPS surprise · last 4Q
Q4 25
-$0.21
Q3 25
-$0.19
Q2 25
-$0.29
Q1 25
-$0.35
Next: May 5, 2026
Revenue trend · last 8Q
—
—
—
—
—
+314%
-58%
+84%
Q1 24
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
$0
$8.2M
$93.8M
$29.2M
$30.8M
$33.9M
$39.8M
$53.7M
Margins · last 8Q
Gross
88.7%
Operating
-51.1%
Profit
-39.6%
Wall Street consensus
5 analysts · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
—
Latest: JP Morgan · Mar 11, 2026
vs Industry
How DAWN stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related